ArticleEndocrine connections2026
Effects of miR-451 on the proliferation, invasion and migration of papillary thyroid cancer cell line TPC-1 by regulating the PI3K/AKT/mTOR signaling pathway.
Article in Endocrine connections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to investigate the effects of miR-451 on proliferation, invasion, and migration of the papillary thyroid carcinoma (PTC) cell line TPC-1, focusing on its regulatory role in the PI3K/AKT/mTOR signaling pathway. Methods: TPC-1 cells were transfected with siRNA-NC, miR-451 mimic, or miR-451 inhibitor and treated with the PI3K activator 740Y-P (miR-451 mimic + 740Y-P) where indicated. Cell proliferation, migration, and invasion were assessed using MTT, wound healing, and transwell assays, respectively. Protein expression and pathway activation were analyzed by western blot. Results: Compared to the blank and siRNA-NC groups, the miR-451 mimic group showed significantly lower expression of Bcl-2, p-PI3K, p-AKT, and p-mTOR proteins, along with significantly higher expression of Bax (P < 0.05). Conversely, the miR-451 inhibitor group exhibited significantly elevated levels of Bcl-2, p-PI3K, p-AKT, and p-mTOR and significantly reduced Bax expression (P < 0.05). Furthermore, compared with the miR-451 mimic group, the miR-451 mimic + 740Y-P group displayed significantly increased expression of Bcl-2, p-PI3K, p-AKT, and p-mTOR, along with significantly decreased Bax levels (P < 0.05). Conclusions: miR-451 expression is significantly reduced in PTC tissues and TPC-1 cells. Overexpression of miR-451 inhibits proliferation, invasion, and migration in TPC-1 cells, likely via the PI3K/AKT/mTOR signaling pathway, suggesting its potential as a molecular target for further investigation in PTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.